| Similar Articles |
|---|
 |
Pharmaceutical Executive
September 1, 2008
Sarah Houlton |
Doing More With Less In order to take a big step forward, GlaxoSmithKline looks to employ smaller licensing deals and business units.   |
Chemistry World
August 23, 2012
Simon Campbell |
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth. |
The Motley Fool
April 5, 2011
Frank Vinluan |
GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep. |
Chemistry World
June 23, 2010
Sarah Houlton |
A smaller future for big pharma? Cutting the amount spent on medicines may be an easy way for governments to help balance the books in the short term, but in the long run it will impact the ability to discover new medicines. |
The Motley Fool
January 7, 2010
Brian Orelli |
Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered. |
Pharmaceutical Executive
September 1, 2010 |
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. |
Pharmaceutical Executive
October 1, 2010 |
Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Chemistry World
May 21, 2009
Matt Wilkinson |
Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
The Motley Fool
June 28, 2010
Luke Timmerman |
Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system. |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
The Motley Fool
April 13, 2010
Brian Orelli |
Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development. |
Chemistry World
April 25, 2014
Andy Extance |
$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees. |
The Motley Fool
April 12, 2011
Brian Orelli |
Merck Joins the Low-Margin Party The American drugmaker announces that it is partnering with Sun Pharma to establish a joint venture to sell branded generics in emerging markets. |
Fast Company
November 2010
Elizabeth Svoboda |
The Myelin Repair Foundation Encourages Collaboration for a Cure Scientists in their labs. Big Pharma in pursuit of the next blockbuster. An innovative foundation brings them together to speed up the discovery of multiple-sclerosis drugs. |
Chemistry World
October 31, 2008
Matt Wilkinson |
GSK Snaps up Hepatitis Drug Developer In a bid to strengthen its efforts to develop new hepatitis therapies, GSK has agreed to buy Genelabs Technologies in a deal worth $57 million. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
Bio-IT World
June 2006
Michael A. Greeley |
Backwards Influence Biotech companies must think downstream as they consider what drugs to develop. Many companies are introducing cost-effectiveness analysis earlier in the discovery process. |
BusinessWeek
October 4, 2004
Kerry Capell |
Why Glaxo Can't Shake the Flu Sales are weakening as hot sellers come off-patent. But the pipeline looks healthy. And there's the rub. Just when GSK's image is at a new low, its prospects are improving. |
Chemistry World
February 4, 2009
Matt Wilkinson |
GSK targets autoimmune biologics GSK recently signed seven drug development deals that could see the company release a suite of drugs to treat inflammatory diseases ranging from rheumatoid arthritis to lupus. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
BusinessWeek
October 18, 2004
Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
Pharmaceutical Executive
January 1, 2011 |
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. |
Chemistry World
September 24, 2010
Andrew Turley |
End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use. |
The Motley Fool
July 31, 2009
Brian Orelli |
Can Emerging Markets Save Pharma? Probably not until after they emerge. |
The Motley Fool
August 12, 2010
Brian Orelli |
Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment. |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
Chemistry World
July 25, 2012 |
Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population. |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
The Motley Fool
June 3, 2011
Frank Vinluan |
GSK Sees Positive Results on Asthma, COPD Drug Expected to Succeed Advair GSK gets good news. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
Pharmaceutical Executive
June 1, 2012 |
2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead. |
Pharmaceutical Executive
July 3, 2007 |
Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future. |
The Motley Fool
April 21, 2009
Brian Orelli |
Reworking the Broken R&D Model When it comes to drug development, it's becoming increasingly clear that competition isn't always the best thing for the industry. Collaborations will help bring drugs to the market more cheaply. |
Pharmaceutical Executive
January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
Chemistry World
October 2, 2013
Phillip Broadwith |
Aspen acquires anticoagulant brands South African generics manufacturer Aspen has bought two heparin-derived thrombosis drugs from GlaxoSmithKline. |
Pharmaceutical Executive
January 1, 2009
Stan Bernard |
Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms. |
The Motley Fool
June 26, 2006
Stephen D. Simpson |
Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note. |
Bio-IT World
December 10, 2002
Jim Hall |
21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives. |
Pharmaceutical Executive
January 1, 2007
Glass & Poli |
Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges. |
Chemistry World
March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
Pharmaceutical Executive
August 1, 2011
Ben Comer |
Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever. |
Pharmaceutical Executive
May 1, 2014
William Looney |
What's Real in Deals Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis: specialization and value differentiation are preferable to sheer bulk. |
Chemistry World
December 15, 2009
Sarah Houlton |
Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu. |
Pharmaceutical Executive
April 1, 2014
Subramanian et al. |
"Market-Based" Price Controls In India? Three strategic implications for pharma pricing strategies in India. |
The Motley Fool
February 26, 2010
Brian Orelli |
Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue. |
Chemistry World
November 21, 2008
Pete Mitchell |
UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry. |
Chemistry World
February 4, 2010
Matt Wilkinson |
More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets. |
